BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Salvadori M, Bertoni E. Is it time to give up with calcineurin inhibitors in kidney transplantation? World J Transplant 2013; 3(2): 7-25 [PMID: 24175203 DOI: 10.5500/wjt.v3.i2.7]
URL: https://www.wjgnet.com/2220-3230/full/v3/i2/7.htm
Number Citing Articles
1
Fuad Shihab, Uwe Christians, Lonnie Smith, Jason R. Wellen, Bruce Kaplan. Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure–response relationships, and clinical outcomesTransplant Immunology 2014; 31(1): 22 doi: 10.1016/j.trim.2014.05.002
2
B. Tönshoff. Minimierung der immunsuppressiven Therapie mit Calcineurininhibitoren nach Nierentransplantation?Der Nephrologe 2015; 10(5): 419 doi: 10.1007/s11560-015-1001-6
3
Hina Khalid, Muhammad Mazhar Fareed, Thomas Dandekar, Sergey Shityakov. Calcineurin and mTOR inhibitors in kidney transplantation: integrative metamodeling on transplant survival and kidney functionInternational Urology and Nephrology 2023; 56(4): 1403 doi: 10.1007/s11255-023-03754-3
4
James Reuberson, Helen Horsley, Richard J. Franklin, Daniel Ford, Judi Neuss, Daniel Brookings, Qiuya Huang, Bart Vanderhoydonck, Ling-Jie Gao, Mi-Yeon Jang, Piet Herdewijn, Anant Ghawalkar, Farnaz Fallah-Arani, Adnan R. Khan, Jamie Henshall, Mark Jairaj, Sarah Malcolm, Eleanor Ward, Lindsay Shuttleworth, Yuan Lin, Shengqiao Li, Thierry Louat, Mark Waer, Jean Herman, Andrew Payne, Tom Ceska, Carl Doyle, Will Pitt, Mark Calmiano, Martin Augustin, Stefan Steinbacher, Alfred Lammens, Rodger Allen. Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in VivoJournal of Medicinal Chemistry 2018; 61(15): 6705 doi: 10.1021/acs.jmedchem.8b00521
5
Robert C. Harland, Goran Klintmalm, Stephen Jensik, Harold Yang, Jonathan Bromberg, John Holman, Mysore S.A. Kumar, Vicki Santos, Tami J. Larson, Xuegong Wang. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority studyAmerican Journal of Transplantation 2020; 20(1): 159 doi: 10.1111/ajt.15591
6
Suwasin Udomkarnjananun, Maaike R. Schagen, Dennis A. Hesselink. A review of landmark studies on maintenance immunosuppressive regimens in kidney transplantationAsian Biomedicine 2024; 18(3): 92 doi: 10.2478/abm-2024-0015
7
Eleanor M Bolton, John Andrew Bradley. Avoiding Immunological Rejection in Regenerative MedicineRegenerative Medicine 2015; 10(3): 287 doi: 10.2217/rme.15.11
8
G. Laham, R. Scuteri, P. Cornicelli, M. Arriola, P.M. Raffaele, M. Davalos Michel, N. Imperiali, R.M. Fortunato, E.C. Maggiora, M.V. Sal, G. Soler Pujol. Surveillance Registry of Sirolimus Use in Recipients of Kidney Allografts From Expanded Criteria DonorsTransplantation Proceedings 2016; 48(8): 2650 doi: 10.1016/j.transproceed.2016.08.008
9
Opas Traitanon, James M Mathew, Giovanna La Monica, Luting Xu, Valeria Mas, Lorenzo Gallon, Derya Unutmaz. Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B CellsPLOS ONE 2015; 10(6): e0129658 doi: 10.1371/journal.pone.0129658
10
Goce Spasovski, Lada Trajceska, Irena Rambabova-Bushljetik. Pharmacotherapeutic options for the prevention of kidney transplant rejection: the evidence to dateExpert Opinion on Pharmacotherapy 2022; 23(12): 1397 doi: 10.1080/14656566.2022.2102418
11
Faouzi Saliba, Christophe Duvoux, Sébastien Dharancy, Jérôme Dumortier, Yvon Calmus, Jean Gugenheim, Nassim Kamar, Ephrem Salamé, Martine Neau‐Cransac, Claire Vanlemmens, François Durand, Georges‐Philippe Pageaux, Jean Hardwigsen, Yasmina Benkhatar, François Derquenne, Filomena Conti. Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE studyLiver International 2022; 42(11): 2513 doi: 10.1111/liv.15396
12
Arthur J. Matas, Robert S. Gaston. Moving Beyond Minimization Trials in Kidney TransplantationJournal of the American Society of Nephrology 2015; 26(12): 2898 doi: 10.1681/ASN.2015030245
13
James M. Neuberger, Wolf O. Bechstein, Dirk R.J. Kuypers, Patrizia Burra, Franco Citterio, Sabina De Geest, Christophe Duvoux, Alan G. Jardine, Nassim Kamar, Bernhard K. Krämer, Herold J. Metselaar, Frederik Nevens, Jacques Pirenne, Manuel L. Rodríguez-Perálvarez, Didier Samuel, Stefan Schneeberger, Daniel Serón, Pavel Trunečka, Giuseppe Tisone, Teun van Gelder. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant RecipientsTransplantation 2017; 101(4S): S1 doi: 10.1097/TP.0000000000001651
14
Agnieszka Urzykowska, Barbara Piątosa, Urszula Grycuk, Grzegorz Kowalewski, Zbigniew Kułaga, Ryszard Grenda. Evaluation of Cumulative Effect of Standard Triple Immunosuppression on Prevention of De Novo Donor Specific Antibodies (dnDSA) Production in Children after Kidney Transplantation—A Retrospective and Prospective StudyChildren 2021; 8(12): 1162 doi: 10.3390/children8121162
15
Fei Liu, Jian-Hua Mao. Calcineurin inhibitors and nephrotoxicity in childrenWorld Journal of Pediatrics 2018; 14(2): 121 doi: 10.1007/s12519-018-0125-y
16
Maria del Carmen Rial, Helio Tedesco Silva, Alvaro Pacheco-Silva, José Cruz, Rodolfo Torres, Bartholomew J. Tortella, Huihua Li, Pablo Cornicelli, Carlos Estevez. Adverse Events and Discontinuation Rates Associated with Sirolimus Treatment in Adult Renal Transplant Patients in Latin America vs Non–Latin American CountriesTransplantation Proceedings 2020; 52(3): 767 doi: 10.1016/j.transproceed.2020.01.040
17
Alberto Baroja-Mazo, Beatriz Revilla-Nuin, Pablo Ramírez, José A Pons. Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantationWorld Journal of Transplantation 2016; 6(1): 183-192 doi: 10.5500/wjt.v6.i1.183
18
Song C. Ong, Robert S. Gaston. Thirty Years of Tacrolimus in Clinical PracticeTransplantation 2021; 105(3): 484 doi: 10.1097/TP.0000000000003350
19
Mark D. Stegall, Robert S. Gaston, Fernando G. Cosio, Arthur Matas. Through a Glass DarklyJournal of the American Society of Nephrology 2015; 26(1): 20 doi: 10.1681/ASN.2014040378
20
Marja van Dijk, Arie M. van Roon, M. Yusof Said, Frederike J. Bemelman, Jaap J. Homan van der Heide, Hans W. de Fijter, Aiko P. J. de Vries, Stephan J. L. Bakker, Jan Stephan F. Sanders. Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trialTransplant International 2018; 31(12): 1380 doi: 10.1111/tri.13322
21
Yoko Kurata, Takafumi Kuzuya, Yuko Miwa, Kenta Iwasaki, Masataka Haneda, Katsuo Amioka, Kiyofumi Yamada, Yoshihiko Watarai, Akio Katayama, Kazuharu Uchida, Takaaki Kobayashi. Clinical relevance of post-transplant pharmacodynamic analysis of cyclosporine in renal transplantationInternational Immunopharmacology 2014; 22(2): 384 doi: 10.1016/j.intimp.2014.07.022
22
Takenori Niioka, Hideaki Kagaya, Mitsuru Saito, Takamitsu Inoue, Kazuyuki Numakura, Ryohei Yamamoto, Yumiko Akamine, Tomonori Habuchi, Shigeru Satoh, Masatomo Miura. Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patientsInternational Journal of Urology 2016; 23(6): 484 doi: 10.1111/iju.13081
23
Jayant Kumar, Isabella Reccia, Francesco Virdis, Mauro Podda, Ajay Kumar Sharma, Ahmed Halawa. Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic reviewWorld Journal of Transplantation 2021; 11(3): 70-86 doi: 10.5500/wjt.v11.i3.70
24
V. Turunç, S.B. Açıkgöz, H. Dheir. Early Switch to Mammalian Target of Rapamycin Inhibitors Is a Sustainable Treatment Approach in Renal Transplant Recipients: 7-Year ResultsTransplantation Proceedings 2019; 51(4): 1070 doi: 10.1016/j.transproceed.2019.01.098
25
Cyd M. Castro-Rojas, Rita R. Alloway, E. Steve Woodle, David A. Hildeman. High-Dimensional Renal Profiling: Towards a Better Understanding of Renal Transplant Immune SuppressionCurrent Transplantation Reports 2019; 6(1): 60 doi: 10.1007/s40472-019-0225-1
26
Fernando Gonzalez. Empirical or unconscious reduction of the secondary immunosuppressive drug concomitantly with intended calcineurin inhibitor reduced exposure to improve kidney graft function can be followed by antibody mediated rejectionsClinical Transplantation 2015; 29(4): 277 doi: 10.1111/ctr.12512
27
Mohammad Hossein Karimi, Saeed Marzban, Mohammad Reza Hajiyan, Bita Geramizadeh, Ali Akbar Pourfathollah, Mohammad Hassan Rajabiyan, Salimeh Ebrahimnezhad. Effect of Cd40 Silenced Dendritic Cells by RNA Interference on Mice Skin Allograft RejectionImmunotherapy 2015; 7(2): 111 doi: 10.2217/imt.14.112
28
L. Song, A. Ma, H. Dun, Y. Hu, Y. Fujii, F. Kinugasa, S. Oshima, Y. Higashi, P. Daloze, H. Chen. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus MonkeysAmerican Journal of Transplantation 2017; 17(3): 635 doi: 10.1111/ajt.14039
29
Experimental and Clinical Transplantation 2017; 15(3) doi: 10.6002/ect.2016.0270